Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
Atezolizumab plus Bevacizumab combination therapy (AtezoBev) is well-known 1st-line therapy
for advanced hepatocellular carcinoma (HCC). However, there are unmet needs for patients with
advanced HCC who do not respond to AtezoBev. External beam radiotherapy (RT) is another
well-known locoregional therapy for HCC that induces inflammatory cascade and abscopal effect
as a systemic anticancer effect and enhances the effect of AtezoBev. Therefore, the
investigators aim to verify the effect of AtezoBev plus RT for advanced HCC through this
single-center, prospective phase II one-armed cohort study over three years. This study
recruits 51 patients to verify the effect of the intervention. Atezolizumab (1200mg) and
Bevacizumab (15mg/kg) are administered to patients once for each cycle at 3-week intervals,
and additional radiotherapy for the mass or portal vein tumor thrombosis is performed before
second cycle of AtezoBev. The primary endpoint is progression-free survival by using response
evaluation with modified RECIST.